Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients

Basit Öğe Kaydı
dc.contributor.authorArtac, Mehmet
dc.contributor.authorKorkmaz, Levent
dc.contributor.authorCoskun, Hasan Senol
dc.contributor.authorDane, Faysal
dc.contributor.authorKarabulut, Bulent
dc.contributor.authorKaraagac, Mustafa
dc.contributor.authorCabuk, Devrim
dc.date.accessioned2024-02-23T13:59:44Z
dc.date.available2024-02-23T13:59:44Z
dc.date.issued2019
dc.departmentNEÜen_US
dc.description.abstractPurposeThe purpose of this study was to investigate whether obesity affects survival in metastatic colorectal cancer (mCRC) patients treated with bevacizumab combined with chemotherapy.MethodsA total of 563 patients with mCRC who had received first-line chemotherapy in combination with bevacizumab were studied. Patients were grouped as obese (BMI levels >30) or non-obese (BMI levels <30). Progression-free survival (PFS) and overall survival (OS) were analyzed. Primary tumor location was also investigated in terms of PFS and OS.ResultsThe median age of the patients was 59years. The non-obese group had longer PFS than the obese group (P=0.030). The 2-year survival rate of the non-obese group was also significantly higher (P=0.036). The median PFS of non-obese patients was significantly longer in Kras wild-type patients (10.1 vs. 8.1months, P=0.010). Among patients with left-sided primary tumor location, median PFS and OS were significantly higher in the non-obese group (PFS non-obese, 11.5months; obese, 8.8months; P=0.002) (OS non-obese, 29.4months; obese, 21.4months; P=0.026).ConclusionsEfficacy of bevacizumab may be lower in obese patients. Among patients with Kras wild-type left-sided tumors treated with bevacizumab-based regimens, the prognosis could be worse for obese patients than that for non-obese patients. There is a need for prospectively designed studies of obese patients to prove the efficacy and dosages of bevacizumab in treatment of mCRC.en_US
dc.identifier.doi10.1007/s12029-017-0047-2
dc.identifier.endpage220en_US
dc.identifier.issn1941-6628
dc.identifier.issn1941-6636
dc.identifier.issue2en_US
dc.identifier.pmid29302856en_US
dc.identifier.scopus2-s2.0-85040030566en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage214en_US
dc.identifier.urihttps://doi.org/10.1007/s12029-017-0047-2
dc.identifier.urihttps://hdl.handle.net/20.500.12452/11307
dc.identifier.volume50en_US
dc.identifier.wosWOS:000466906100005en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal Of Gastrointestinal Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMetastatic Colorectal Canceren_US
dc.subjectBevacizumaben_US
dc.subjectBody Mass Indexen_US
dc.subjectObesityen_US
dc.subjectK-Rasen_US
dc.titleBevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu